What Are The Latest Key Statistics for ResMed (ASX:RMD) Shares?

Sonal Goyal

09 July 2026 11:47 PM AEST

What Are The Latest Key Statistics for ResMed (ASX:RMD) Shares?

Image Source: Shutterstock

You are reading a free article with opinions that may differ from the recommendation given by Kalkine in its paid research reports. Become a Kalkine member today to get access to our research reports, in-depth technical and fundamental research. Learn more

Start Your Free Trial Now!

Highlights

ResMed (ASX: RMD) shares fell 2.82% during the latest trading session.
Trading volume exceeded the stock's average daily turnover amid active market participation.
ResMed traded at a P/E ratio of 19.84 with a market capitalisation of AUD 44.98 billion.

ResMed Inc. (ASX:RMD) shares traded lower during the latest trading session, declining 2.82% to AUD 30.310 from the previous close of AUD 31.190. The healthcare equipment and services company recorded elevated trading activity as investors tracked movements across the healthcare sector.

Listed on the Australian Securities Exchange (ASX), ResMed had a market capitalisation of approximately AUD 44.98 billion based on the latest available trading data.

RMD Shares Trade Lower

ResMed shares traded between an intraday low of AUD 29.680 and a high of AUD 30.310 during the latest session. The latest quoted price matched the day's high, while the stock was bid at AUD 30.160 and offered at AUD 30.350.

The decline of AUD 0.879 represented a 2.82% decrease from the previous closing price. Despite the latest decline, the stock remained above its 52-week low of AUD 25.500 while trading below its 52-week high of AUD 45.250.

Trading Volume Exceeds Average

The stock recorded trading volume of approximately 2.22 million shares during the latest session. This exceeded the average daily trading volume of approximately 1.61 million shares, indicating higher-than-usual investor participation.

ResMed has approximately 1.44 billion CDI 10:1 Foreign Exempt NYSE securities on issue, resulting in a market capitalisation of around AUD 44.98 billion at the latest trading price.

The company was trading at a price-to-earnings (P/E) ratio of 19.84, based on the latest available market data.

Company Overview

ResMed Inc. operates in the Health Care Equipment & Services industry group and has been listed on the ASX since 25 November 1999 under the ticker RMD.

The company's ASX-listed securities are structured as CDI 10:1 Foreign Exempt NYSE and carry the International Securities Identification Number (ISIN) AU000000RMD6.

Companies operating in the healthcare equipment sector may experience share price movements influenced by product demand, regulatory developments, healthcare reimbursement policies, earnings announcements, innovation, and broader market conditions.

Market Snapshot

ResMed shares declined during the latest trading session while recording trading volume above the stock's historical average. The shares continue to trade within their 52-week range of AUD 25.500 to AUD 45.250.

Market participants continue monitoring price movements, valuation metrics such as the P/E ratio, trading volumes, and broader healthcare sector developments.

Key Risks

Regulatory changes may affect product approvals and commercial operations.
Healthcare reimbursement policies can influence product demand.
Currency fluctuations may impact reported financial performance.
Market volatility can affect short-term share price movements.

Summary

ResMed (ASX: RMD) shares declined 2.82% to AUD 30.310 during the latest trading session after closing at AUD 31.190 previously. The stock traded between AUD 29.680 and AUD 30.310, with trading volume of approximately 2.22 million shares, above its average daily turnover. ResMed has a market capitalisation of approximately AUD 44.98 billion and was trading at a P/E ratio of 19.84.

FAQs

Q: What was ResMed's latest share price?

A:ResMed shares traded at AUD 30.310, down 2.82% from the previous closing price of AUD 31.190.

Q: What is ResMed's current P/E ratio?

A:Based on the latest market data, ResMed was trading at a price-to-earnings (P/E) ratio of 19.84.

Q: What is ResMed's market capitalisation?

A:ResMed had a market capitalisation of approximately AUD 44.98 billion during the latest trading session.

Download Free Report – Explore 3 Stock Ideas & Industry Insights

Unlock 3 stock ideas and key industry insights in our free report. This information is general in nature and does not consider your personal objectives, financial situation, or needs. It is not financial advice.

All investments involve risk—consider independent advice before making any investment decisions.

View 3 Research Reports

Disclaimer:

This article (“Article”) has been prepared by Kalkine Pty Limited (ABN 34 154 808 312) (Australian financial services licence number 425376) (“Kalkine”) and its related bodies corporate who are authorised to provide general financial product advice. Kalkine.com.au and its associated pages are published by Kalkine.

Any information/advice provided in this article is general in nature and does not take into account your objectives, financial situation or needs. You should therefore consider whether the information is appropriate for your objectives, financial situation and needs before acting upon it.

There may be a Product Disclosure Statement, Information Memorandum or other offer document (“Offer Document”) for the securities or other financial products referred to in Kalkine articles. You should obtain a copy of the Offer Document and consider it before making any decision about whether to acquire the security or financial product.

Kalkine strongly recommends that you seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice) before acting on any advice/information in this Article or on the Kalkine website. Not all investments are appropriate for all people.

The information in this Article and on Kalkine website has been prepared from a wide variety of sources, which Kalkine, to the best of its knowledge and belief, considers accurate. Kalkine has made every effort to ensure the reliability of the information contained in its articles (including this Article), newsletters and websites. All information represents our views at the date of publication and may change without notice.

The information in this Article does not constitute an offer to sell securities or other financial products or a solicitation of an offer to buy securities or other financial products.

Kalkine does not issue, sell or deal in any financial products.

This Article may contain information on past performance of particular investments. Please note past performance is neither an indicator nor a guarantee of future performance.

To the extent permitted by law, and excluding any dishonesty or gross negligence by Kalkine, Kalkine disclaims and excludes all liability for any direct, indirect, implied, punitive, special, incidental or other consequential loss or damage arising from the use of or reliance on this Article, the Kalkine website and any information published on the Kalkine website without any warranties or representations by Kalkine to you. To the extent the law prohibits or limits this exclusion, Kalkine limits its liability to the resupply of services.

Please also read our Terms & Conditions and Financial Services Guide for further information.

Employees and/or associates of Kalkine and its related entities may hold interests in the securities or other financial products covered in this Article or on the Kalkine website. Any such employees and associates are required to comply with certain safeguards, procedures and disclosures as required by law.

Some of the images/music that may be used in the Article are copyright to their respective owner(s). Kalkine does not claim ownership of any of the pictures displayed/music used in the Article unless stated otherwise. The images/music that may be used in the Article are taken from various sources on the internet, including paid subscriptions or are believed to be in public domain. We have used reasonable efforts to accredit the source wherever it was indicated or was found to be necessary.

Kalkine Media Pty Ltd, an affiliate of Kalkine Pty Ltd, may have received, or be entitled to receive, financial consideration in connection with providing information about certain entity(s) covered on its website.